Small-molecule AMPK activation preserves anabolic signaling in a C2C12 myotube cachexia model

AMP-activated protein kinase (AMPK) is a master metabolic regulator that responds to a decline in cellular energy status by promoting processes that generate ATP, while inactivating anabolic processes that consume ATP, thereby restoring the energy charge of the cell. In line with this general function, acute AMPK activation in healthy muscle cells potently inhibits anabolic signaling through the mechanistic target of rapamycin (mTORC1). However, treatment of atrophying muscle (from tumor-bearing mice and cells cultured in tumor cell-conditioned media) with the non-specific AMPK activator AICAR suggests that AMPK has a protective effect on muscle mass and anabolic signaling. We have identified MLX-0867 as a novel AMPK-activating small molecule (EC50 = 32.0 mM in C2C12 myotubes). We hypothesized that similar to AICAR, treatment with MLX-0867 would also preserve muscle mass and anabolic mTORC1 signaling in cultured muscle subjected to hyperinflammatory signaling. To test this, we treated C2C12 myotubes with control media (CM) or CM + 20 ng/mL TNF-ɑ and 100 U/mL interferon-γ (T/I) for 24 hours. Additionally, the cells were concurrently treated with 250 mM AICAR, 40 mM MLX-0867 (a novel AMPK activating small-molecule), or vehicle control during the treatment period. To visualize myotubes, myosin heavy chain (MHC) was detected by immunofluorescence, and average myotube diameter was measured. In a separate experiment, the protein was extracted from treated myotubes to determine the phosphorylation of p-70S6k and ribosomal protein S6 (rpS6) as markers of anabolic signaling through mTORC1. We found that T/I treatment significantly decreased myotube diameter. Neither AICAR nor MLX-0867 attenuated this atrophy. However, while T/I substantially reduced S6k and rpS6 phosphorylation, MLX-0867 (but not AICAR) partially preserved the phosphorylation of rpS6 and tended (p=0.11) to preserve p-70S6k phosphorylation under T/I treatment. In summary, MLX-0867 partially preserved anabolic signaling in T/I treated myotubes. However, this did not preserve muscle mass, at least under the conditions utilized in this experiment. A Brigham Young University Widtsoe Grant and a sponsored research agreement with Biolexis Therapeutics funded this research. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.